A Phase 2a Randomized, Double-blind, Placebo-controlled rial to Assess the safety, Immunogenicity, and Efficacy of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Volunteers

Study title: 
A Phase 2a Randomized, Double-blind, Placebo-controlled rial to Assess the safety, Immunogenicity, and Efficacy of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Volunteers
Long title: 
A Phase 2a Randomized, Double-blind, Placebo-controlled rial to Assess the safety, Immunogenicity, and Efficacy of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Volunteers
Date receipt dossier: 
24 Apr 2018
EudraCT number: 
2017-004582-27
Company / Sponsor: 
Bavarian Nordic A/S
Phase: 
IIa
Treated organism: 
Humans
Indication category: 
Infectious disease
Disease: 
Acute respiratory illness caused by RSV
Therapeutic approach: 
Prevention
Genetic modification: 
Vaccinia virus Ankara strain expression glycoproteins of different RSV strain (MVA-BN)
Method of transfer of nucleic acid of interest: 
not applicable
Administered biological material: 
Recombinant vaccinia virus (MVA-BN)
Route of administration: 
Intramuscular
Locations in Belgium: 
SGS Belgium NV
Type of procedure: 
Contained use only
Current status: 
Assessed